Assessment of the effect of the COVID-19 pandemic on UK HbA1c testing: implications for diabetes management and diagnosis.


Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 23 06 2021
accepted: 08 09 2021
pubmed: 15 10 2021
medline: 25 2 2023
entrez: 14 10 2021
Statut: ppublish

Résumé

The COVID-19 pandemic, and the focus on mitigating its effects, has disrupted diabetes healthcare services worldwide. We aimed to quantify the effect of the pandemic on diabetes diagnosis/management, using glycated haemoglobin (HbA1c) as surrogate, across six UK centres. Using routinely collected laboratory data, we estimated the number of missed HbA1c tests for 'diagnostic'/'screening'/'management' purposes during the COVID-19 impact period (CIP; 23 March 2020 to 30 September 2020). We examined potential impact in terms of: (1) diabetes control in people with diabetes and (2) detection of new diabetes and prediabetes cases. In April 2020, HbA1c test numbers fell by ~80%. Overall, across six centres, 369 871 tests were missed during the 6.28 months of the CIP, equivalent to >6.6 million tests nationwide. We identified 79 131 missed 'monitoring' tests in people with diabetes. In those 28 564 people with suboptimal control, this delayed monitoring was associated with a 2-3 mmol/mol HbA1c increase. Overall, 149 455 'screening' and 141 285 'diagnostic' tests were also missed. Across the UK, our findings equate to 1.41 million missed/delayed diabetes monitoring tests (including 0.51 million in people with suboptimal control), 2.67 million screening tests in high-risk groups (0.48 million within the prediabetes range) and 2.52 million tests for diagnosis (0.21 million in the pre-diabetes range; ~70 000 in the diabetes range). Our findings illustrate the widespread collateral impact of implementing measures to mitigate the impact of COVID-19 in people with, or being investigated for, diabetes. For people with diabetes, missed tests will result in further deterioration in diabetes control, especially in those whose HbA1c levels are already high.

Identifiants

pubmed: 34645702
pii: jclinpath-2021-207776
doi: 10.1136/jclinpath-2021-207776
doi:

Substances chimiques

Glycated Hemoglobin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

177-184

Subventions

Organisme : Department of Health
ID : HCS/08/011
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

David Holland (D)

The Benchmarking Partnership, Alsager, UK.

Adrian H Heald (AH)

Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK.
The School of Medicine and Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK.

Mike Stedman (M)

Res Consortium, Andover, UK.

Fahmy Hanna (F)

Department of Diabetes and Endocrinology, Univerisity Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
Centre for Health and Development, Staffordshire University Faculty of Health Sciences, Stoke-on-Trent, UK.

Pensee Wu (P)

Academic Department of Obstetrics and Gynaecology, Univerisity Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.
School of Medicine, Keele University, Keele, UK.

Christopher Duff (C)

School of Medicine, Keele University, Keele, UK.
Department of Clinical Biochemistry, Univerisity Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.

Lewis Green (L)

Department of Clinical Biochemistry, St Helens and Knowsley Teaching Hospitals NHS Trust, Prescot, UK.

Sarah Robinson (S)

Department of Clinical Biochemistry, Univerisity Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.

Ian Halsall (I)

Department of Clinical Biochemistry, Addenbrooke's Hospital, Cambridge, UK.

Neil Gaskell (N)

Department of Pathology, Warrington & Halton Teaching Hospitals NHS Foundation Trust, Warrington, UK.

John Pemberton (J)

Diabetes UK (North Staffordshire Branch), Stoke, UK.

Christine Bloor (C)

Diabetes UK (North Staffordshire Branch), Stoke, UK.

Anthony A Fryer (AA)

School of Medicine, Keele University, Keele, UK a.a.fryer@keele.ac.uk.
Department of Clinical Biochemistry, Univerisity Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH